Not provided
Not provided
Not provided
Not provided
Not enough patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
According perinatal surveys, induction of labor is performed at more than 20% of pregnant women.
According to a survey on the trigger practices in France, prostaglandins are widely used to initiate cervical ripening, usually by laying intravaginal dinoprostone (Propess®).
The overall work-up rate due to the use of a single Propess® is 74.6% with 80% of vaginal deliveries.
Currently, 25.4% of patients who was not put in work after 24 hours are triggered by oxytocin (Syntocinon®) or directly caesarean. The initial installation of intravaginal dinoprostone limits the use of oxytocin (Syntocinon®) or in lower doses.
Using a second Propess® is carried out in several maternity hospitals, as reported by the survey on the cervical ripening practices in France. This second administration could be the solution to reduce the rate of caesarean in France which amounted to 20.8%.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dinoprostone | Experimental | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient. |
|
| Oxytocine | Active Comparator | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dinoprostone | Drug | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient. |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of deliveries vaginally | The rate of births vaginally in each arm | At delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Failure of induction of labor | The failure of induction of labor correspond to cervical dilation remaining <3cm despite 6 hours of Syntocinon (or 1 syringe) and regular uterine contractions and amniotomy. The success of the trigger is defined by regular uterine contractions and cervical dilatation ≥ 3 cm. | At delivery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Perrine COSTE-MAZEAU, MD | University Hospital, Limoges | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CH de Blois | Blois | 41250 | France | |||
| CH de BRIVE |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31915047 | Derived | Coste Mazeau P, Hessas M, Martin R, Eyraud JL, Margueritte F, Aubard Y, Sallee C, Sire F, Gauthier T. Is there an interest in repeating the vaginal administration of dinoprostone (Propess(R)), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial. Trials. 2020 Jan 8;21(1):51. doi: 10.1186/s13063-019-3985-0. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Oxytocine | Drug | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient. |
|
| Time of work |
Time in minutes between the start of work defined by the onset of regular uterine contractions and cervical dilation ≥3 cm and delivery. |
| delivery time |
| Caesarean indications | Caesarean indications | At delivery |
| Proportion of instrumental delivery | The proportion of instrumental delivery | At delivery |
| Proportion of complications of delivery and various care. | The proportion of complications of delivery and various care. | Day 1 |
| Proportion of complete uterine rupture | The proportion of complete uterine rupture | At delivery |
| Transfer in Intensive Care Unit | The transfer in Intensive Care Unit | 10 Days |
| Maternal death | Maternal death | 10 Days |
| Hospital stay of mother | Hospital stay of mother | 10 Days |
| Apgar score | Determination of Apgar score | 3 Min, 5 Min and 10 Min |
| Visual estimation of presence of amniotic fluid meconium | Visual estimation of presence of meconium in amniotic fluid. Absence of meconium if transparent and presence if colored. | At the birth |
| Proportion of transfer neonatal or newborn intensive care unit | The proportion of transfer neonatal or newborn intensive care unit | At the birth |
| Fetal / neonatal death | Fetal / neonatal death | At the birth |
| Assessment of fetal acidosis by measuring of pH, lactates and base excess | Assessment of fetal acidosis by measuring of pH, lactates and base excess | At the birth |
| Brive-la-Gaillarde |
| 19100 |
| France |
| CH Metropole Savoie | Chambéry | 73011 | France |
| Hôpital d'Estaing - CHU de Clermont-Ferrand | Clermont-Ferrand | 63100 | France |
| CHU de LIMOGES | Limoges | 87045 | France |
| Hôpital Nord - APHM | Marseille | 13015 | France |
| CH de TULLE | Tulle | 19012 | France |
| ID | Term |
|---|---|
| D015232 | Dinoprostone |
| ID | Term |
|---|---|
| D011458 | Prostaglandins E |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |
Not provided
Not provided